Status:

COMPLETED

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

Lead Sponsor:

Jazz Pharmaceuticals

Collaborating Sponsors:

FDA Office of Orphan Products Development

Conditions:

Severe Hepatic Veno-Occlusive Disease

Eligibility:

All Genders

Phase:

PHASE3

Brief Summary

The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endot...

Detailed Description

This is a historically-controlled, multicenter, open label Phase 3 study to determine the safety and efficacy of 25 mg/kg/day of Defibrotide (DF) for the treatment of severe VOD in hematopoietic stem ...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of VOD, defined by jaundice (bilirubin \>/= 2 mg/dL) and at least 2 of the following clinical findings, by Day+21 post stem cell transplant: ascites; weight gain \>/= 5% above baseline weight; hepatomegaly.
  • Severe VOD, defined as VOD with multi-organ failure, i.e., presence of one or both of the following, by Day+28 post stem cell transplant: renal or pulmonary dysfunction.
  • Provide voluntary written informed consent.

Exclusion

  • Pre-existing (prior to SCT) cirrhosis
  • An alternative diagnosis for weight gain, ascites and jaundice
  • Graft-versus-host disease (GVHD) grade B or higher involving liver or gut or grade C or higher involving skin
  • Prior solid organ transplant
  • Dependent on dialysis prior to and/or at the time of SCT
  • Dependent on oxygen supplementation prior to SCT
  • Significant acute bleeding or hemodynamic instability
  • Requirement for the use of any medications that increase risk of hemorrhage will be excluded from the treatment group

Key Trial Info

Start Date :

July 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2015

Estimated Enrollment :

134 Patients enrolled

Trial Details

Trial ID

NCT00358501

Start Date

July 1 2006

End Date

March 1 2015

Last Update

January 30 2017

Active Locations (25)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (25 locations)

1

Duarte, California, United States

2

Palo Alto, California, United States

3

Denver, Colorado, United States

4

Atlanta, Georgia, United States

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients | DecenTrialz